In December 2024, the FDA approved Zepbound™ (tirzepatide) for a second use beyond weight management: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It was the first medication the FDA had approved specifically for this form of sleep apnea, and the news drew attention well beyond the world of diabetes and weight-loss medicine. If you or someone you know uses a CPAP machine, or has been told a sleep study shows OSA, it's a reasonable moment to ask what this approval actually means, who it's for, and how it fits alongside the sleep apnea treatments that already exist.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation, including a sleep study and a clinician's assessment of your specific health history.
Why sleep apnea and weight are connected
Obstructive sleep apnea happens when the muscles supporting the soft tissue in the throat relax too much during sleep, letting the upper airway narrow or briefly collapse. Each episode can partially or fully block airflow, often followed by a brief awakening the person doesn't remember, then loud snoring or gasping as breathing resumes. Over a full night these interruptions can happen many times, fragmenting sleep and reducing the amount of oxygen reaching the bloodstream.
Excess weight, particularly fat that accumulates around the neck and upper airway, is one of the most well established risk factors for OSA. Extra tissue in that area can narrow the airway even during the day, and that narrowing becomes more pronounced once muscle tone relaxes during sleep. This is part of why weight and sleep apnea are so often discussed together clinically, and why weight reduction has long been part of standard OSA management advice, even before any medication was approved specifically for the condition.
Not everyone with OSA has obesity, and not everyone with obesity has OSA; airway anatomy, age, and family history also play a role. But where excess weight is a significant contributor, it creates a clear rationale for why a medication that supports meaningful weight reduction might also ease OSA symptoms.
What the FDA approved, and who it's for
In December 2024, the FDA approved Zepbound™ (tirzepatide) injection for moderate-to-severe obstructive sleep apnea in adults with obesity, to be used together with a reduced-calorie diet and increased physical activity. This was an expansion of Zepbound's™ original 2023 approval for chronic weight management, not a brand-new medication. Tirzepatide, the active ingredient in Zepbound™, is a dual GIP and GLP-1 receptor agonist, a class of medication also used in Mounjaro® for type 2 diabetes.
The approval applies specifically to adults with obesity who have been diagnosed with moderate-to-severe OSA, generally confirmed through a sleep study. It is not a blanket approval for anyone who snores or suspects they might have sleep apnea, and it does not apply to people with mild OSA or to people without obesity. A licensed clinician determines whether someone meets the criteria for this indication, starting with an accurate diagnosis rather than symptoms alone.
It's also worth being precise about which product this covers. The FDA approval is specific to Zepbound™, the FDA-approved brand of tirzepatide. Compounded tirzepatide, prepared by a licensed compounding pharmacy, is not FDA-approved for any use, including obstructive sleep apnea, and has not been reviewed by the FDA for safety, efficacy, or quality; it may be prescribed by an independent licensed physician when clinically appropriate, such as during an FDA-declared shortage.
How tirzepatide is thought to help with OSA
Tirzepatide's OSA indication is understood to work largely through weight reduction rather than a separate, direct effect on the airway itself. By activating GIP and GLP-1 receptors, tirzepatide affects appetite regulation and can support meaningful reductions in body weight when combined with a reduced-calorie diet and increased physical activity. Because excess weight around the neck and upper airway is a central driver of OSA in many people with obesity, weight reduction can ease the physical narrowing that leads to airway collapse during sleep.
This mechanism lines up with older, non-medication approaches to OSA. Clinicians have long recommended weight management, alongside other lifestyle measures, as one part of caring for OSA in people with obesity, precisely because weight reduction has been shown to improve OSA severity for some patients. What's new with the Zepbound™ approval is that it's the first time the FDA has approved a medication specifically for this indication, backed by clinical trial data collected for that purpose rather than inferred from general weight-management studies.
What the clinical trial evidence showed
The FDA's approval was based on clinical trials in adults with obesity and moderate-to-severe OSA. Sleep apnea severity in these trials was measured using tools such as the apnea-hypopnea index (AHI), which counts the average number of breathing interruptions per hour of sleep. Participants who received tirzepatide showed reductions in the number of breathing interruptions during sleep compared with those who received placebo, alongside the expected reduction in body weight.
As with any clinical trial, individual results varied, and not everyone who takes tirzepatide will see the same degree of change in OSA severity. Outcomes for an individual patient depend on many factors, including how OSA is diagnosed, how consistently a medication is used, and each person's broader health picture, which is why the decision to use tirzepatide for OSA is made individually with a clinician rather than assumed from headline results.
| Approach | What it does | Considerations |
|---|---|---|
| CPAP | Delivers steady air pressure through a mask to keep the airway open overnight | Effective for many people; nightly use matters, and some find the mask takes adjustment |
| Weight-focused treatment | Aims to reduce excess weight around the neck and upper airway that contributes to narrowing | Zepbound™ (tirzepatide) is FDA-approved for moderate-to-severe OSA with obesity; suitability is determined by a clinician |
| Oral appliances | Custom-fitted devices that reposition the jaw or tongue to help keep the airway open | Often considered for mild-to-moderate OSA or when CPAP isn't well tolerated |
| Other measures | Positional therapy, or in select cases surgical options | Suitability depends on individual anatomy and OSA severity, determined after an evaluation |
CPAP, other OSA treatments, and where medication fits
Continuous positive airway pressure (CPAP) therapy remains a standard, well established treatment for moderate-to-severe OSA. A CPAP machine delivers steady air pressure through a mask during sleep, keeping the airway open and preventing the repeated collapses that define the condition. For many people, CPAP is effective and is often the first treatment a clinician recommends after a diagnosis.
The FDA's approval of tirzepatide for OSA does not replace CPAP or other established treatments; it was studied in combination with, not instead of, existing care. Some people using tirzepatide for OSA continue CPAP alongside it. Whether and when to adjust or step down CPAP use is a decision the treating clinician makes based on follow-up sleep studies and the individual's response to treatment, not something decided by the patient alone or assumed simply because a person has lost weight.
Talking to a clinician about an evaluation
If you think you might have OSA, whether because of loud snoring, gasping during sleep, or persistent daytime fatigue, the starting point is a proper evaluation, not guessing based on symptoms alone. A clinician can review your health history, discuss your symptoms, and determine whether a sleep study is appropriate to confirm a diagnosis and establish severity.
For people who already have a confirmed OSA diagnosis and are also managing obesity, it's worth bringing up specifically whether a GLP-1 or GIP/GLP-1 medication might be relevant to their care, alongside their existing sleep treatment plan. A few things tend to make that conversation more useful:
- Your current OSA severity and how it was diagnosed, whether through an in-lab or at-home sleep study.
- Whether you currently use CPAP or another OSA treatment, and how consistently.
- Your full weight and metabolic health history, since eligibility for a GLP-1 medication depends on more than OSA alone.
- Any other conditions or medications you take, since tirzepatide has its own contraindications and warnings separate from OSA treatment.
You can read more about how compounded and FDA-approved tirzepatide compare in our guide to compounded tirzepatide vs Zepbound™, and about digestive side effects that can come up with GLP-1 medications more broadly in side effects of GLP-1 medications. If a procedure or surgery is coming up during treatment, our article on GLP-1 medications and surgery covers what your care team may ask about timing. Sleep apnea comes up in other treatment contexts too; see our related article on testosterone therapy and sleep apnea if that applies to you.
The bottom line
The Zepbound™ approval for moderate-to-severe OSA in adults with obesity marks the first time the FDA has approved a medication specifically for this indication. It doesn't replace CPAP or other established OSA treatments, and it isn't relevant to everyone with OSA; eligibility depends on an accurate diagnosis, weight status, and a clinician's assessment of the full picture. Compounded tirzepatide, unlike Zepbound™, is not FDA-approved for this or any use. If sleep apnea and weight are both part of your health picture, the most useful next step is an honest conversation with a licensed clinician about what a comprehensive evaluation would look like for you.
You can find more on related topics in our Weight Management section.
Important Safety Information
Indication. Tirzepatide (Zepbound™) is FDA-approved for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity, each used alongside a reduced-calorie diet and increased physical activity. Tirzepatide is also FDA-approved under the brand name Mounjaro® for type 2 diabetes. Compounded tirzepatide is not FDA-approved for any use and has not been reviewed by the FDA for safety, efficacy, or quality; it may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. Injection site reactions have also been reported. These are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors seen in rodent studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about any history of pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
What did the FDA actually approve for GLP-1 medications and sleep apnea?
In December 2024, the FDA approved Zepbound™ (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, in addition to its existing approval for chronic weight management. Both uses are meant to be combined with a reduced-calorie diet and increased physical activity, and the sleep apnea indication requires a confirmed diagnosis, not symptoms alone.
Does this mean semaglutide (Ozempic® or Wegovy®) is approved for sleep apnea too?
No. The FDA's obstructive sleep apnea approval applies specifically to tirzepatide (Zepbound™), not to semaglutide products such as Ozempic® or Wegovy®. Semaglutide and tirzepatide act on related but not identical receptor pathways, and each medication's FDA-approved indications are specific to the trials that supported them.
How does tirzepatide help with obstructive sleep apnea?
Tirzepatide's effect on obstructive sleep apnea is understood to work mainly through weight reduction. Because excess weight around the neck and upper airway is a major contributor to airway narrowing during sleep for many people with obesity, reducing that weight can ease the physical mechanics behind the condition, rather than acting on the airway directly.
Should I stop using my CPAP machine if I start tirzepatide?
Not without talking to your clinician first. Tirzepatide's sleep apnea approval doesn't replace CPAP or other established treatments, and it was studied alongside standard care, not as a substitute for it. Whether and when to adjust CPAP use is a decision your treating clinician makes based on follow-up evaluation.
Is compounded tirzepatide FDA-approved for sleep apnea?
No. The FDA's obstructive sleep apnea approval applies specifically to Zepbound™, the FDA-approved brand of tirzepatide. Compounded tirzepatide is not FDA-approved for any use, including obstructive sleep apnea, and has not been reviewed by the FDA for safety, efficacy, or quality, though it may be prescribed by an independent licensed physician when clinically appropriate.
How do I know if I'm a candidate for this treatment?
Candidacy depends on having a confirmed diagnosis of moderate-to-severe obstructive sleep apnea, generally through a sleep study, along with obesity and an overall health picture a clinician reviews individually. An online evaluation is a starting point for that conversation, but it does not guarantee that any specific treatment will be prescribed.
